At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 214 enrolled
Drug / intervention
Candesartan Cilexetil +2 moredrug
Likely dose
Candesartan Cilexetil 16 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults
In Brief
A Phase 4 clinical trial evaluating Candesartan Cilexetil and Hydrochlorothiazide for Stage II Hypertension. Completed, enrolled 214 participants across 1 site.
Detailed Summary
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage II Hypertension
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedFeb 22, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.4 years ago
Interventions
Candesartan Cilexetildrug
Candesartan Cilexetil 16 mg oral
Hydrochlorothiazidedrug
Hydrochlorothiazide 12.5 mg
Candesartan Cilexetildrug
Candesartan Cilexetil 32 mg oral